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The protozoan parasite Trypanosoma cruzi, the eti-
ological agent of Chagas’ disease, affects millions
of individuals and continues to be an important glo-
bal health concern. The poor efficacy and unfavor-
able side effects of current treatments necessitate
novel therapeutics. Cruzain, the major cysteine pro-
tease of T. cruzi, is one potential novel target.
Recent advances in a class of vinyl sulfone inhibi-
tors are encouraging; however, as most potential
therapeutics fail in clinical trials and both disease
progression and resistance call for combination
therapy with several drugs, the identification of
additional classes of inhibitory molecules is essen-
tial. Using an exhaustive virtual-screening and
experimental validation approach, we identify sev-
eral additional small-molecule cruzain inhibitors.
Further optimization of these chemical scaffolds
could lead to the development of novel drugs useful
in the treatment of Chagas’ disease.
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The World Health Organization estimates that over 10 million peo-
ple are infected by the protozoan parasite Trypanosoma cruzi, with
another 25 million at riska. The associated illness, called Chagas'
disease, is spread through a triatomine vector or through blood
transfusion (1,2). The acute phase lasts at most a few months and
is characterized by mild symptoms such as fever, malaise, facial
edema, generalized lymphadenopathy, and hepatosplenomegaly. In
approximately 30% of infected patients, parasite multiplication via
asynchronous cycles contributes to the chronic stage of the disease,
with the associated cell destruction, reinfection within the reticulo-
endothelial system, and organ infection (3). Infection of the heart,
digestive tract, and central nervous system can lead to fatal heart-
rhythm abnormalities, megacolon, and dementia, respectively (4,5).
Trypanosoma cruzi is not susceptible to many of the drugs used to
treat closely related parasites like Trypanosoma brucei. Benznidazole
and nifurtimox are the only available therapies for acute-phase Cha-
gas' disease. These nitroheterocyclics are highly toxic and have
poor efficacy in long-lasting chronic infections (6–8). No extensive
studies of the long-term sequellae of these therapeutics have been
conducted in humans, but several reports of neuropathy and tumori-
genic or carcinogenic effects have been described (6,7). Efforts to
develop a vaccine against T. cruzi have also failed thus far, likely
because the disease pathology has an autoimmune component (9).
The major T. cruzi cysteine proteinase cruzain (also referred to as cru-
zipain, the full-length native enzyme) has been shown to be crucial for
all stages of the parasite life cycle. This papain-like cysteine protease
is thought to play an important role in differentiation, cell invasion,
intracellular multiplication, and immune evasion (10,11). Furthermore,
studies have demonstrated that cysteine proteinase inhibitors have
trypanocidal activity with negligible mammalian toxicity (12).
Previous efforts have identified vinyl sulfones, sulfonates, and sulf-
onamides as high-affinity cruzain inhibitors (13,14); one of these
vinyl sulfones, K11777, is currently undergoing Investigational New
Drug enabling studies (15,16). a-ketoamide-, a-ketoacid, a-ketoest-
er-, aldehyde-, and ketone-based inhibitors have also been
described (17–19). While these successes are encouraging, many
potential drugs, including those that enter clinical trials, ultimately
fail to gain approval (20), and those that are approved are subject
to growing parasitic resistance. Consequently, a diverse set of
inhibitory scaffolds that can be optimized into distinct therapeutic
candidates is urgently needed.
Hoping to contribute to this ever-growing diverse set of compounds,
we here use an advanced virtual-screening methodology that
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accounts for receptor flexibility to identify three promising non-cova-
lent inhibitors of T. cruzi cruzain.
Experimental Methods
Ligand preparation
A small-molecule library was prepared from the ligands of the NCI
Diversity Set II using the Schrçdinger LIGPREP programb. Protonation
states were assigned at pH 5.5 to mimic the natural acidic environ-
ment of the T. cruzi digestive vacuole. Multiple tautomers and ste-
reoisomers were generated. One ligand could not be processed by
LIGPREP; instead, Discovery Studioc was used to add hydrogen atoms
to this ligand and to optimize its geometry.
Initial screen against the crystal structure
The prepared ligand models of this small-molecule library were
docked into a 1.20  crystal structure of cruzain (PDB ID: 1ME4) (18),
with hydrogen atoms included using PDB2PQR (21,22) at pH 5.5. Res-
idues CYS25 and H159 (called H162 by some) formed the thiolate–
imidazolium pair required for the catalytic mechanism (23) of the pro-
teinase at this pH. This initial virtual screen was performed using
the CDOCKER docking softwarec with a docking sphere 15  in diame-
ter centered on the coordinates of the crystallographic ligand.
Rescoring protocol
The CDOCKER-predicted pose of each ligand model was rescored
using six additional scoring functions: LigScore1, LigScore2 (24),
PLP1, PLP2 (25), PMF (26), and PMF04 (27). The best-scoring models
as evaluated using each of these seven scoring functions were
compiled into a new small-molecule library of 302 models (182
unique ligands) enriched for predicted cruzain inhibitors.
Molecular dynamics simulations
The molecular dynamics simulations used in the current study have
been described previously (28). In brief, the simulations were based
on a 1.20  cruzain crystal structure (PDB ID: 1ME4) (18) protonated
at pH 5.5 to mimic the natural acidic environment of the T. cruzi
digestive vacuole. Following appropriate minimization and equilibra-
tion, five distinct 20-ns simulations of the cruzain protein bound to
a hydroxymethyl ketone inhibitor, [1-(1-BENZYL-3-HYDROXY-2-OXO-
PROPYLCARBAMOYL)-2-PHENYL-ETHYL]-CARBAMIC ACID BENZYL
ESTER, were performed. The gromos clustering algorithm (29) was
used to cluster 4002 conformations extracted from the simulations
every 50 fs. We found that decreasing the cutoff below 0.95 
resulted in a precipitous rise in the number of clusters; conse-
quently, we chose an RMSD cutoff of 0.95 , which yielded 24
clusters. The central member of each cluster, considered most rep-
resentative, was selected for subsequent analysis; this set of cen-
tral members is said to constitute an ensemble.
Relaxed -complex screen
The 302 compound models of the enriched small-molecule library
were docked into the 24 clusters of the ensemble using CDOCKER
(Accelrys). Each of these docked small-molecule models was re-
scored with the following scoring functions: LigScore2 (24), PLP1,
PLP2 (25), PMF (26), and PMF04 (27). For each ligand ⁄ scoring func-
tion pair, an ensemble-average score was calculated according to
the following equation:
E ¼
P23
i¼1
wiEi
P23
i¼1
wi
ð1Þ
where E is the weighted ensemble-average score, wi is the size of
cluster i, and Ei is the best score of each unique ligand, indepen-
dent of tautomeric or stereoisomeric form, docked into the centroid
of cluster i.
Two methods were used to select compounds for subsequent exper-
imental validation. First, for each of the five scoring functions, the
compounds were ranked from best to worst by the ensemble-aver-
age score. The top seven compounds were selected from each of
these five ordered lists and merged into a single list of potential
binders. Second, the average rank of each compound across all five
scoring functions was calculated. The compounds were then reor-
dered by this average rank, and the top thirty were likewise identi-
fied as potential binders. Any compound indicated by either of
these two protocols was subsequently recommended for preliminary
experimental validation.
Enzymatic assays
Each compound was obtained from the National Cancer Institute's
Development Therapeutics Program, which guaranteed 90% purity.
Compounds were tested for cruzain enzymatic inhibition using a
protocol that has been described previously (30). The eight com-
pounds with the lowest IC50 values were assessed for aggregation
by observing enzymatic activity under varying experimental condi-
tions. As detergent is known to disrupt colloidal aggregation (31),
inhibition in the absence of detergent was compared with inhibition
in the presence of Triton X-100 (0.02%) and Tween (0.002%). The
reducing agent was also varied (10 mM DTT or 10 mM Beta-Mercap-
toethanol). Each experimental condition was tested in at least two
separate experiments. Finally, a dynamic light scattering technique,
described in detail elsewhere (32), was applied to the top four com-
pounds to further confirm the presence or absence of aggregation.
Additional experimental details can be found in the Supporting
Information.
Final pose predictions
All compounds submitted for experimental validation were subse-
quently docked a final time into the binding pocket of the crystal
structure (PDB ID: 1ME4) using the Induced Fit Docking (IFD) module
of the Maestro 9.2 (Schrçdinger, LLC) computer package with Glide
XP precision (33,34). For each of the top three nonaggregating
ligands, the best-scoring pose that positioned the inhibitor near the
crucial catalytic triad was selected and visualized using PYMOLd.
Although the top poses using this IFD protocol were generally simi-
lar to those from the relaxed complex scheme (RCS) CDOCKER work,
Novel Inhibitors of T. cruzi Cruzain
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we choose to show them here in the commonly represented crystal
structure conformation for ease of recognition to the reader of sub-
sites within the well-characterized active site of cruzain.
Results and Discussion
Discovered by Carlos Chagas in 1909 (35,36), T. cruzi is one of only
two known pathogenic Trypanosoma species. Current trypanocidal
therapeutics like nifurtimox and benznidazole are inadequate
because they are toxic (6–8), subject to growing resistance (37),
and ineffective at eradicating the parasite and preventing cardiomy-
opathy over the long term (38). Given the dire need for novel thera-
pies, we here use virtual-screening methods to identify three
promising inhibitors of cruzain, a critical cysteine protease required
for T. cruzi survival.
Weaknesses of virtual-screening
Virtual-screening techniques have been used to identify a number
of inhibitors in recent years [see, for example, references (39–45)].
Though widely used, these screens are often characterized by many
false positives and negatives. Two principal weaknesses explain
these inaccuracies. First, there are errors intrinsic to the scoring
functions themselves. Because virtual-screening efforts often
attempt to identify true binders from among the many thousands of
molecules in a compound library, they are generally optimized for
speed at the expense of accuracy. Second, current docking pro-
grams account for, at best, only limited receptor flexibility. When a
small-molecule binder encounters its receptor in vivo, that receptor
often undergoes conformational rearrangements or an 'induced fit'
to better accommodate the ligand. These holo conformations can
differ significantly from those of x-ray crystallographic structures.
Even if the perfect docking scoring function did exist, it could not
accurately predict binding affinity if receptor flexibility were
ignored. In the current work, we use a scheme designed to mini-
mize both these sources of error.
Overcoming inaccuracies inherent to the
scoring functions themselves
The ligands of the NCI Diversity Set IIe were initially docked into a
cruzain crystal structure using CDOCKERc because this program was
able to capture the crystallographic poses of two positive controls.
Docking with AutoDock (46) was initially performed, but docked and
crystallographic poses differed significantly. The CDOCKER-docked
poses were subsequently rescored using several different scoring
functions, and potential binders were selected by consensus rather
than by the score of any single function. Consensus scoring has two
advantages. First, when multiple scoring functions are combined, the
errors of each may in part cancel out (47). Second, different scoring
functions likely have different intrinsic weaknesses and strengths.
Some, for example, may better account for hydrophobic contacts,
while others better capture electrostatic interactions. When com-
bined, accuracy may be improved if the weaknesses and strengths
of the constituent functions are complementary (48).
The scoring functions used in the current work come from different
classes and thus provide independent assessments of ligand binding
that may be complementary. Scoring functions fall into one of three
categories: force field, empirical, and knowledge-based. Force field
scoring functions like that used by CDOCKER, based on the CHARMm
force field, evaluate ligand binding by accounting for bonded and
nonbonded atomic interactions explicitly. Empirical scoring functions
like LigScore1, LigScore2, PLP1, and PLP2 are based on counting
the number of different types of receptor-ligand interactions (e.g.,
hydrogen-bond and hydrophobic interactions) as well as countable
changes in molecular properties (e.g., the number of rotatable
bonds immobilized upon ligand binding). Finally, knowledge-based
scoring functions like PMF and PMF04 are based on statistical anal-
yses of large structural databases like subsets of the Protein Data
Bank (49). Intermolecular interactions that occur more often than
expected by pure chance are assumed to be energetically favorable.
The top candidate binders from this initial crystal structure screen,
as judged by consensus scoring, were compiled into a single list of
302 small-molecule models that were subsequently subjected to fur-
ther study.
Overcoming inaccuracies caused by ignoring
full receptor flexibility
While consensus scoring may have helped overcome in part the
errors intrinsic to each individual scoring function, those caused by
ignoring receptor flexibility remained. To overcome this second chal-
lenge, we first studied receptor dynamics by performing five distinct
20-ns molecular dynamics simulations of cruzain, described else-
where (28). The protein conformations sampled during these simula-
tions were clustered into 24 groups using an RMSD-based
clustering algorithm (29). Each of the centroid members of each
cluster, considered to be the most representative, was identified,
and the group of all centroids is said to constitute an ensemble.
Having identified multiple cruzain conformations, we redocked the
302 small-molecule models identified in the initial crystal structure
screen into each of the 24 members of the ensemble, again using
CDOCKER. The ligands were then reranked by an ensemble-average
score that was not dependent on a single crystal structure but
rather accounted for receptor flexibility. This multireceptor docking
protocol, called the RCS, has been used successfully in the past to
identify inhibitors of FKBP (40), HIV integrase (39), and T. brucei
RNA editing ligase 1 (41), among others (42–44).
Final rescoring
As each of the 302 small-molecule models was docked into 24 dif-
ferent cruzain conformations, there were 7248 docked poses in all.
Each of these 7248 poses was rescored, again using multiple scor-
ing functions. Ensemble-average scores were calculated for each
scoring function, and the 302 small-molecule models were appropri-
ately ranked.
Two criteria were used to identify likely inhibitors from among
these ranked compounds. First, we selected the seven best inhibi-
tors as predicted by each of the individual scoring functions and
merged them into a single list of 22 candidates. Second, the top 30
predicted ligands as judged by the ensemble-average rank were
Rogers et al.
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likewise identified. In all, 37 unique candidate inhibitors were
selected; of these, the best 30 were tested experimentally.
Predicted binding modes
Of the 30 compounds tested, eight inhibited cruzain at 100 lM (Fig-
ure 1, all structures below the first arrow). Using standard condi-
tions, the best-scoring compound had an initial IC50 value of
471 nM (see Figure 1, asterisk). Subsequent experiments suggested
that this compound inhibited cruzain non-specifically via aggregation
(Supporting Information). Fortunately, three other compounds,
although less potent, did in fact appear to inhibit cruzain specifi-
cally (Supporting Information). These three compounds, NSC
227186, NSC 67436, and NSC 260594, have IC50 values of 16, 63,
and 66 lM, respectively (see Figure 1, bottom row). While these
compounds lack the nanomolar affinity characteristic of approved
drugs, they do possess the low micromolar affinity typical of lead
compounds. With proper optimization, including fragment addition,
moiety swapping, and similarity searching, these compounds could
be transformed into viable drug candidates. We are hopeful that
these new leads will be helpful to those in the drug discovery com-
munity targeting Chagas' disease.
Figure 2 shows the predicted binding poses (a, c, e) and important
interactions (b, d, f) associated with each of the three most promis-
ing compounds using the IFD protocol and visualized in PYMOL
(described in Experimental Methods). Figure 2B shows the predicted
polar contacts of NSC 227186 with GLN19, THR185, and TRP184;
TRP184 is also oriented for possible aromatic stacking with one of
the ligand aromatic moieties. GLU208 (called GLU205 by some) is
predicted to swing even further away from the cruzain S2 sub-
site than is seen in the 1ME4 crystal structure, allowing a ligand
Figure 1: The structures of all experimentally validated compounds. Associated IC50 values are given for the top three non-aggregating
inhibitors. Means and standard deviations were calculated by considering all IC50 values associated with each compound, measured under
varying experimental conditions as described in the Experimental Methods (n = 8). *NSC 61610 appears to inhibit cruzain nonspecifically via
aggregation (see the Supporting Information).
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methylpyrrolidine moiety to occupy the site, reminiscent of the Phe
and Tyr rings of several known inhibitors (13–18,50,51). An oxane
moiety is also predicted to occupy the S3¢ subsite (13).
NSC 67436 (Figure 2D) is predicted to form even more interactions
with the cruzain receptor, including various hydrogen-bond interac-
tions with residues GLN19, GLY66, ALA141, ASP161, and ASN182,
as well as possible aromatic stacking with HIS162. Two distinct cy-
clohexanamine moieties are predicted to occupy the S2 and S1¢
subsites, and a chlorocyclohexane (4-chlorocyclohexane-1,3-dicarbal-
dehyde) moiety is predicted to bind near S1. S4 and S3¢ are also
occupied, both with distinct imidazoline rings (13).
Figure 2F shows the hydrogen bonds predicted to form between
NSC 260594 and MET68, ASN69, and ASP161. Again reminiscent
of several known ligands, the S2 subsite is occupied by an aromatic
ring system, and a slightly rotated GLU208 accommodates the lar-
ger aromatic moiety (1-methyl-6-nitro-decahydroquinolin-4-amine).
In an attempt to identify predicted binding characteristics that might
aid the identification of future inhibitors, we used the IFD module
of the Schrçdinger Maestro computer package to re-dock the 30
experimentally tested compounds into a crystallographic active site
model (PDB ID: 1ME4) at pH 5.5. Unlike CDOCKER docking, the IFD
protocol allows for local active site conformational changes and so
is judged to better predict ligand binding, albeit at the cost of
speed. The most favorable IFD poses of the validated inhibitors (Fig-
ure 2) consistently placed ligand atoms near the catalytic triad in a
position that could conceivably compromise cruzain enzymatic activ-
ity. Additionally, the IFD poses of these compounds also place at
least one aromatic ring in the S2 subsite, a site known to be favor-
able for the binding of Phe and Tyr aromatic side chains (13–
18,50,51).
These predicted binding poses are promising because they repre-
sent unique scaffolds that differ significantly from those of previ-
ously identified small-molecule inhibitors. While the poses included
here are mere predictions, we are hoped that they will guide future
optimization of these experimentally validated ligands.
Conclusions
Chagas' disease is the leading cause of heart failure in Latin Amer-
ica, affecting over 10 million individuals worldwide. Although pro-
gress has been made in the treatment of the disease, especially
A B
C D
E
F
Figure 2: The predicted binding poses and receptor-ligand interactions of the experimentally validated inhibitors. A, C, and E: Compounds
and cruzain active sites are shown in stick and surface representation, respectively. Active site domains are also labeled (S1–S3, S1¢, S3¢).
The poses shown were obtained using the Induced Fit Docking module of the Schrçdinger Maestro computer package. B, D, and F: The pre-
dicted receptor-ligand interactions, with hydrogen bonds represented as black dotted lines. Residues predicted to participate in receptor-ligand
interactions, as well as the residues of the catalytic triad, are visualized.
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given the recent success of K11777, multiple cruzain inhibitors are
needed given the difficulty of obtaining FDA approval and ever-pro-
gressing drug resistance. The work presented here provides chemi-
cal scaffolds that, with further optimization, could be developed
into promising therapeutics for Chagas' disease. The exhaustive vir-
tual-screening approach and thorough experimental validation used
to identify these leads also represents a promising and useful
method for inhibitor identification.
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